Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Co-lead program. Phase 2 ORCA-SURGE in moderate-to-severe PsO initiated Feb 2026 with data expected Q1 2027; Phase 2 ORCA-SPLASH in HS initiated.
ORKA-004
Preclinical · ActiveModality: monoclonal antibody
Target TL1A
Indications
not disclosed(Preclinical)
Catalysts
— Q4 2026 / 2027
Status note Subcutaneously administered anti-TL1A mAb; planned for development in combination with ORKA-001 and ORKA-002.
ORKA-003
Stage not disclosed · ActiveModality: n/a
Indications
not disclosed(Stage not disclosed)
Status note Fourth program targeting an undisclosed pathway; no stage disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.